In this task, you are given text for US Congressional and California state bills, your task is to generate a summary for this bill.

Input: Consider Input: SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Right to Try Act''.

SEC. 2. USE OF UNAPPROVED MEDICAL PRODUCTS BY PATIENTS DIAGNOSED WITH A 
              TERMINAL ILLNESS.

    (a) In General.--Notwithstanding the Federal Food, Drug, and 
Cosmetic Act (21 U.S.C. 301 et seq.), the Controlled Substances Act (21 
U.S.C. 801 et seq.), and any other provision of Federal law, the 
Federal Government shall not take any action to prohibit or restrict--
            (1) the production, manufacture, distribution, prescribing, 
        or dispensing of an experimental drug, biological product, or 
        device that--
                    (A) is intended to treat a patient who has been 
                diagnosed with a terminal illness; and
                    (B) is authorized by, and in accordance with, State 
                law; and
            (2) the possession or use of an experimental drug, 
        biological product, or device--
                    (A) that is described in subparagraphs (A) and (B) 
                of paragraph (1); and
                    (B) for which the patient has received a 
                certification from the patient's treating physician in 
                accordance with subsection (b).
    (b) Physician Certification.--A certification by the patient's 
treating physician referred to in subsection (a)(2)(B) must include 
each of the following:
            (1) A certification that the physician--
                    (A) is in good standing with the physician's 
                certifying organization or board; and
                    (B) has personally examined the patient.
            (2) A certification that there is no reason to conclude the 
        experimental drug, biological product, or device poses an 
        unreasonable and significant risk of danger to the patient.
            (3) A certification that the patient has been diagnosed 
        with a terminal disease or condition and does not have any 
        treatment options that--
                    (A) are comparable to treatment using the 
                experimental drug, biological product, or device or 
                otherwise satisfactory; and
                    (B) are approved, licensed, or cleared for 
                commercial distribution under section 505, 510(k), or 
                515 of the Federal Food, Drug, and Cosmetic Act (21 
                U.S.C. 355, 360(k), 360(e)) or section 351 of the 
                Public Health Service Act (42 U.S.C. 262) and are 
                available to diagnose, monitor, or treat the patient's 
                disease or condition.
            (4) A certification that the probable risk to the patient 
        from the experimental drug, biological product, or device is 
        not greater than the probable risk from the patient's disease 
        or condition.
            (5) A certification that the physician has provided the 
        patient with a written statement and oral explanation of the 
        medical treatment to be provided using the experimental drug, 
        biological product, or device.
            (6) An acknowledgement signed by the patient (or the 
        patient's legal representative) that the physician has provided 
        the written statement and oral explanation required by 
        paragraph (5), and has disclosed the following:
                    (A) That the medical treatment using the 
                experimental drug, biological product, or device is 
                experimental or nonconventional.
                    (B) That the experimental drug, biological product, 
                or device has not been approved, licensed, or cleared 
                for commercial distribution under section 505, 510(k), 
                or 515 of the Federal Food, Drug, and Cosmetic Act (21 
                U.S.C. 355, 360(k), 360(e)) or section 351 of the 
                Public Health Service Act (42 U.S.C. 262) for any 
                indication.
                    (C) The material risks generally recognized by a 
                reasonably prudent physician of the medical treatment's 
                side effects.
                    (D) An explanation of the medical treatment, 
                including the expected frequency and duration of the 
                treatment.
    (c) No Liability or Use of Outcomes.--
            (1) No liability.--Notwithstanding any other provision of 
        law, no liability shall lie against a producer, manufacturer, 
        distributor, prescriber, dispenser, possessor, or user of an 
        experimental drug, biological product, or device for the 
        production, manufacture, distribution, prescribing, dispensing, 
        possession, or use of an experimental drug, biological product, 
        or device that is in compliance, with subsection (a).
            (2) No use of outcomes.--Notwithstanding any other 
        provision of law, the outcome of any production, manufacture, 
        distribution, prescribing, dispensing, possession, or use of an 
        experimental drug, biological product, or device that was done 
        in compliance with subsection (a) shall not be used by a 
        Federal agency reviewing the experimental drug, biological 
        product, or device to delay or otherwise adversely impact 
        review or approval of such experimental drug, biological 
        product, or device.
    (d) Rules of Construction.--Nothing in this Act shall be construed 
to--
            (1) require a manufacturer or other person to make 
        available any experimental drug, biological product, or device; 
        or
            (2) prohibit a manufacturer or other person from receiving 
        compensation or recovering costs for the production, 
        manufacture, distribution, or sale of an experiment drug, 
        biological product, or device.
    (e) Definitions.--In this section:
            (1) Biological product.--The term ``biological product'' 
        has the meaning given to such term in section 351 of the Public 
        Health Service Act (42 U.S.C. 262).
            (2) Device; drug.--The terms ``device'' and ``drug'' have 
        the meanings given to such terms in section 201 of the Federal 
        Food, Drug, and Cosmetic Act (21 U.S.C. 321).
            (3) Experimental drug, biological product, or device.--The 
        term ``experimental drug, biological product, or device'' means 
        a drug, biological product, or device that--
                    (A) has successfully completed a phase 1 clinical 
                investigation;
                    (B) remains under investigation in a clinical trial 
                approved by the Food and Drug Administration; and
                    (C) is not approved, licensed, or cleared for 
                commercial distribution under section 505, 510(k), or 
                515 of the Federal Food, Drug, and Cosmetic Act (21 
                U.S.C. 355, 360(k), 360(e)) or section 351 of the 
                Public Health Service Act (42 U.S.C. 262).
            (4) Phase 1 clinical investigation.--The term ``phase 1 
        clinical investigation'' means a phase 1 clinical 
        investigation, as described in section 312.21 of title 21, Code 
        of Federal Regulations (or any successor regulations).
            (5) Terminal illness.--The term ``terminal illness'' has 
        the meaning given to such term in the State law specified in 
        subsection (a)(1)(B).

Output: Right to Try Act This bill requires the federal government to allow unrestricted manufacturing, distribution, prescribing, and dispensing of experimental drugs, biological products, and medical devices that are authorized by state law and intended to treat terminally ill patients. Patients receiving these treatments must be certified by a physician as having exhausted all other treatment options and as being at greater risk from their medical condition than the treatment. The physician must explain the treatment to the patient, including that the treatment is experimental, and the patient, or the patient's legal representative, must acknowledge the explanation. A manufacturer, distributor, prescriber, dispenser, possessor, or user of such a treatment has no liability regarding the treatment. The outcome of manufacture, distribution, prescribing, dispensing, possession, or use of such a treatment may not be used by a federal agency to adversely impact review or approval of the treatment. The treatment must: (1) have successfully completed a phase 1 (initial, small scale) clinical trial; (2) remain under investigation in a clinical trial approved by the Food and Drug Administration (FDA); and (3) not be approved, licensed, or cleared for sale by the FDA.  


Input: Consider Input: SECTION 1. PERMANENT EXTENSION OF ESTATE TAX AS IN EFFECT IN 2009.

    (a) Exclusion Equivalent of Unified Credit Equal to $3,500,000.--
Subsection (c) of section 2010 of the Internal Revenue Code of 1986 
(relating to unified credit against estate tax) is amended to read as 
follows:
    ``(c) Applicable Credit Amount.--
            ``(1) In general.--For purposes of this section, the 
        applicable credit amount is the amount of the tentative tax 
        which would be determined under section 2001(c) if the amount 
        with respect to which such tentative tax is to be computed were 
        equal to the applicable exclusion amount.
            ``(2) Applicable exclusion amount.--
                    ``(A) In general.--For purposes of this subsection, 
                the applicable exclusion amount is $3,500,000.
                    ``(B) Inflation adjustment.--In the case of any 
                decedent dying in a calendar year after 2010, the 
                dollar amount in subparagraph (A) shall be increased by 
                an amount equal to--
                            ``(i) such dollar amount, multiplied by
                            ``(ii) the cost-of-living adjustment 
                        determined under section 1(f)(3) for such 
                        calendar year by substituting `calendar year 
                        2009' for `calendar year 1992' in subparagraph 
                        (B) thereof.
                If any amount as adjusted under the preceding sentence 
                is not a multiple of $10,000, such amount shall be 
                rounded to the nearest multiple of $10,000.''.
    (b) Maximum Estate Tax Rate Equal to 45 Percent.--
            (1) In general.--Subsection (c) of section 2001 of the 
        Internal Revenue Code of 1986 (relating to imposition and rate 
        of tax) is amended--
                    (A) by striking ``but not over $2,000,000'' in the 
                table contained in paragraph (1),
                    (B) by striking the last 2 items in such table,
                    (C) by striking ``(1) in general.--'', and
                    (D) by striking paragraph (2).
            (2) Conforming amendment.--Paragraphs (1) and (2) of 
        section 2102(b) of such Code are amended to read as follows:
            ``(1) In general.--A credit in an amount that would be 
        determined under section 2010 as the applicable credit amount 
        if the applicable exclusion amount were $60,000 shall be 
        allowed against the tax imposed by section 2101.
            ``(2) Residents of possessions of the united states.--In 
        the case of a decedent who is considered to be a `nonresident 
        not a citizen of the United States' under section 2209, the 
        credit allowed under this subsection shall not be less than the 
        proportion of the amount that would be determined under section 
        2010 as the applicable credit amount if the applicable 
        exclusion amount were $175,000 which the value of that part of 
        the decedent's gross estate which at the time of the decedent's 
        death is situated in the United States bears to the value of 
        the decedent's entire gross estate, wherever situated.''.
    (c) Modifications of Estate and Gift Taxes To Reflect Differences 
in Unified Credit Resulting From Different Tax Rates.--
            (1) Estate tax.--
                    (A) In general.--Section 2001(b)(2) of the Internal 
                Revenue Code of 1986 (relating to computation of tax) 
                is amended by striking ``if the provisions of 
                subsection (c) (as in effect at the decedent's death)'' 
                and inserting ``if the modifications described in 
                subsection (g)''.
                    (B) Modifications.--Section 2001 of such Code is 
                amended by adding at the end the following new 
                subsection:
    ``(g) Modifications to Gift Tax Payable To Reflect Different Tax 
Rates.--For purposes of applying subsection (b)(2) with respect to 1 or 
more gifts, the rates of tax under subsection (c) in effect at the 
decedent's death shall, in lieu of the rates of tax in effect at the 
time of such gifts, be used both to compute--
            ``(1) the tax imposed by chapter 12 with respect to such 
        gifts, and
            ``(2) the credit allowed against such tax under section 
        2505, including in computing--
                    ``(A) the applicable credit amount under section 
                2505(a)(1), and
                    ``(B) the sum of the amounts allowed as a credit 
                for all preceding periods under section 2505(a)(2).
        For purposes of paragraph (2)(A), the applicable credit amount 
        for any calendar year before 1998 is the amount which would be 
        determined under section 2010(c) if the applicable exclusion 
        amount were the dollar amount under section 6018(a)(1) for such 
        year.''.
            (2) Gift tax.--Section 2505(a) of such Code (relating to 
        unified credit against gift tax) is amended by adding at the 
        end the following new flush sentence:
``For purposes of applying paragraph (2) for any calendar year, the 
rates of tax in effect under section 2502(a)(2) for such calendar year 
shall, in lieu of the rates of tax in effect for preceding calendar 
periods, be used in determining the amounts allowable as a credit under 
this section for all preceding calendar periods.''.
    (d) Effective Date.--The amendments made by this section shall 
apply to estates of decedents dying, generation-skipping transfers, and 
gifts made, after December 31, 2009.
    (e) Additional Modifications to Estate Tax.--
            (1) In general.--Subtitles A and E of title V of the 
        Economic Growth and Tax Relief Reconciliation Act of 2001, and 
        the amendments made by such subtitles, are hereby repealed; and 
        the Internal Revenue Code of 1986 shall be applied as if such 
        subtitles, and amendments, had never been enacted.
            (2) Sunset not to apply.--
                    (A) Subsection (a) of section 901 of the Economic 
                Growth and Tax Relief Reconciliation Act of 2001 is 
                amended by striking ``this Act'' and all that follows 
                and inserting ``this Act (other than title V) shall not 
                apply to taxable, plan, or limitation years beginning 
                after December 31, 2010.''.
                    (B) Subsection (b) of such section 901 is amended 
                by striking ``, estates, gifts, and transfers''.
            (3) Repeal of deadwood.--
                    (A) Sections 2011, 2057, and 2604 of the Internal 
                Revenue Code of 1986 are hereby repealed.
                    (B) The table of sections for part II of subchapter 
                A of chapter 11 of such Code is amended by striking the 
                item relating to section 2011.
                    (C) The table of sections for part IV of subchapter 
                A of chapter 11 of such Code is amended by striking the 
                item relating to section 2057.
                    (D) The table of sections for subchapter A of 
                chapter 13 of such Code is amended by striking the item 
                relating to section 2604.
    (f) Sense of the Senate Regarding Revenue Neutrality.--It is the 
sense of the Senate that any reduction in Federal revenues resulting 
from the provisions of, and amendments made by, this section should be 
fully offset.

Output: Amends the Internal Revenue Code to: (1) restore the unified credit against the estate and gift tax after 2009; (2) establish the amount of such credit at $3.5 million adjusted for inflation in calendar years after 2010; and (3) reduce the maximum estate and gift tax rate to 45%.

Expresses the sense of the Senate that any reduction in federal revenues resulting from this Act should be fully offset.


Input: Consider Input: SECTION 1. SHORT TITLE.

    This Act may be cited as the ``American 5-Cent Coin Design 
Continuity Act of 2002''.

SEC. 2. DESIGNS ON THE 5-CENT COIN COMMEMORATING THE BICENTENNIAL OF 
              THE LOUISIANA PURCHASE.

    (a) In General.--Subject to subsection (b) and after consulting 
with the Coin Design Advisory Committee and the Commission of Fine 
Arts, the Secretary of the Treasury may change the design on the 
obverse and the reverse of the 5-cent coin for coins issued in 2003, 
2004, and 2005 in commemoration of the bicentennial of the Louisiana 
Purchase.
    (b) Design Specifications.--
            (1) Obverse.--If the Secretary of the Treasury elects to 
        change the obverse of 5-cent coins issued during 2003, 2004, 
        and 2005, the design shall include an image of President Thomas 
        Jefferson in commemoration of his role with respect to the 
        Louisiana Purchase and the commissioning of the Louis and Clark 
        Expedition to explore the newly acquired territory.
            (2) Reverse.--If the Secretary of the Treasury elects to 
        change the reverse of the 5-cent coins issued during 2003, 
        2004, and 2005, the design selected shall commemorate the 
        Louisiana Purchase.
            (3) Other inscriptions.--5-cent coins issued during 2003, 
        2004, and 2005 shall continue to meet all other requirements 
        for inscriptions and designations applicable to circulating 
        coins under section 5112(d)(1) of title 31, United States Code.

SEC. 3. DESIGNS ON THE 5-CENT COIN SUBSEQUENT TO THE COMMEMORATION OF 
              THE BICENTENNIAL OF THE LOUISIANA PURCHASE.

    (a) In General.--Section 5112(d)(1) of title 31, United States 
Code, is amended by inserting after the 4th sentence the following new 
sentences: ``The obverse of any 5-cent coin issued after December 31, 
2005, shall bear an image of Thomas Jefferson. The reverse of any 5-
cent coin issued after December 31, 2005, shall bear an image of the 
home of Thomas Jefferson at Monticello.''.
    (b) Design Consultation.-- The 2d sentence of section 5112(d)(2) of 
title 31, United States Code, is amended by inserting ``, after 
consulting with the Coin Design Advisory Committee and the Commission 
of Fine Arts,'' after ``The Secretary may''.

SEC. 4. COIN DESIGN ADVISORY COMMITTEE.

    (a) In General.--Subchapter III of chapter 51 of title 31, United 
States Code, is amended by inserting after section 5136 (as amended by 
section 5 of this Act) the following new section:
``Sec. 5137. Coin Design Advisory Committee
    (a) Establishment.--There is hereby established the Coin Design 
Advisory Committee (in this section referred to as the ``Advisory 
Committee'').
    ``(b) Membership.--
            (1) Appointment.--The Advisory Committee shall consist of 9 
        members, as follows:
                    ``(A) The Chief of Staff to the Secretary of the 
                Treasury.
                    ``(B) 4 persons appointed by the President--
                            ``(i) 1 of whom shall be appointed for a 
                        term of 4 years from among individuals who are 
                        specially qualified to serve on the Advisory 
                        Committee by virtue of their education, 
                        training, or experience as a nationally or 
                        internationally recognized curator in the 
                        United States of a numismatic collection;
                            ``(ii) 1 of whom shall be appointed for a 
                        term of 4 years from among individuals who are 
                        specially qualified to serve on the Advisory 
                        Committee by virtue of their experience in the 
                        medallic arts or sculpture;
                            ``(iii) 1 of whom shall be appointed for a 
                        term of 3 years from among individuals who are 
                        specially qualified to serve on the Advisory 
                        Committee by virtue of their education, 
                        training, or experience in American history; 
                        and
                            ``(iv) 1 of whom shall be appointed for a 
                        term of 2 years from among individuals who are 
                        specially qualified to serve on the Advisory 
                        Committee by virtue of their education, 
                        training, or experience in numismatics.
                    ``(C) 1 person appointed by the Speaker of the 
                House of Representatives from among individuals who are 
                specially qualified to serve on the Advisory Committee 
                by virtue of their education, training, or experience, 
                including staff employees of the House of 
                Representatives, who shall serve at the pleasure of the 
                Speaker.
                    ``(D) 1 person appointed by the minority leader of 
                the House of Representatives from among individuals who 
                are specially qualified to serve on the Advisory 
                Committee by virtue of their education, training, or 
                experience, including staff employees of the House of 
                Representatives, who shall serve at the pleasure of the 
                minority leader.
                    ``(E) 1 person appointed by the majority leader of 
                the Senate from among individuals who are specially 
                qualified to serve on the Advisory Committee by virtue 
                of their education, training, or experience, including 
                staff employees of the Senate, who shall serve at the 
                pleasure of the majority leader.
                    ``(F) 1 person appointed by the minority leader of 
                the Senate from among individuals who are specially 
                qualified to serve on the Advisory Committee by virtue 
                of their education, training, or experience, including 
                staff employees members of the Senate, who shall serve 
                at the pleasure of the minority leader.
            ``(2) Continuation of service.--Each appointed member may 
        continue to serve after the expiration of the term of office to 
        which such member was appointed until a successor has been 
        appointed and qualified.
            ``(3) Vacancy.--
                    ``(A) In general.--Any vacancy on the Advisory 
                Committee shall be filled in the manner in which the 
                original appointment was made.
                    ``(B) Acting officials may serve.--In the event of 
                a vacancy in a position described in paragraph (1)(A), 
                and pending the appointment of a successor, or during 
                the absence or disability of any individual serving in 
                any such position, any individual serving in an acting 
                capacity in any such position may serve on the Advisory 
                Committee while serving in such capacity.
            ``(4) Chairperson.--The Chairperson of the Advisory 
        Committee shall be the person serving in the position described 
        in paragraph (1)(A) (or serving in an acting capacity in such 
        position).
            ``(5) Pay and expenses.--Members of the Advisory Committee 
        shall serve without pay for such service but each member of the 
        Advisory Committee shall be reimbursed from the United States 
        Mint Public Enterprise Fund for expenses incurred in connection 
        with attendance of such members at meetings of the Advisory 
        Committee.
            ``(6) Meetings.--The Advisory Committee shall meet, not 
        less frequently than quarterly, at the call of the chairperson 
        or a majority of the members.
            ``(7) Quorum.--7 members of the Advisory Committee shall 
        constitute a quorum.
    ``(c) Duties of the Advisory Committee.--The duties of the Advisory 
Committee are as follows:
            ``(1) Advise the Secretary of the Treasury on any design 
        proposals relating to circulating coinage and numismatic items, 
        including congressional gold medals.
            ``(2) Advise the Secretary of the Treasury with regard to 
        any other proposals or issues relating to any items produced by 
        the United States Mint that the Secretary may request of the 
        Advisory Committee.
    ``(d) Administrative Support Services.--Upon the request of the 
Advisory Committee, the Director of the United States Mint shall 
provide to the Advisory Committee the administrative support services 
necessary for the Advisory Committee to carry out its responsibilities 
under this section.
    ``(e) Annual Report.--
            ``(1) Required.--Not later than January 30 of each year, 
        the Advisory Committee shall submit a report to the Committee 
        on Financial Services of the House of Representatives and the 
        Committee on Banking, Housing, and Urban Affairs of the Senate.
            ``(2) Contents.--The report required by paragraph (1) shall 
        describe the activities of the Advisory Committee during the 
        preceding year and the reports and recommendations made by the 
        Advisory Committee to the Secretary of the Treasury.
    ``(f) Federal Advisory Committee Act Does Not Apply.--The Federal 
Advisory Committee Act shall not apply with respect to the Committee, 
except that each meeting of the Advisory Committee shall be open to the 
public following publication of a notice of the meeting in the Federal 
Register.''.

            Passed the House of Representatives July 22, 2002.

            Attest:

                                                 JEFF TRANDAHL,

                                                                 Clerk.


Output: American 5-Cent Coin Design Continuity Act of 2002 - Authorizes the Secretary of the Treasury to change the design on the obverse and reverse sides of five-cent coins issued in 2003, 2004, and 2005 to commemorate the bicentennial of the Louisiana Purchase. States that: (1) if the Secretary elects to change the obverse side design, the new design shall include an image of President Thomas Jefferson in commemoration of his role with respect to the Louisiana Purchase and the commissioning of the Louis and Clark Expedition; and (2) if the reverse side depiction is changed, the new design shall commemorate the Louisiana Purchase.Amends Federal law to declare that after December 31, 2005, any five-cent coin issued shall bear on its obverse side an image of Thomas Jefferson, and on its reverse side an image of Jefferson's home at Monticello.Establishes the Coin Design Advisory Committee to advise the Secretary on any design proposals relating to circulating coinage and numismatic items, and any other proposals or issues relating to items produced by the United States Mint as the Secretary may request.